Figure 3From: Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational studyPercentages of patients with (A) minimal important difference ≥0.22 on the Health Assessment Questionnaire Disability Index (HAQ DI) and (B) normal function defined as HAQ DI ≤0.5 over long-term adalimumab (ADA) treatment. Observed data are reported. LO, last observation.Back to article page